{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:25:31Z","timestamp":1786926331540,"version":"build-2736575974"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-74255-x","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:55:56Z","timestamp":1783536956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4403-3217","authenticated-orcid":false,"given":"Van","family":"To","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niko","family":"Thio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Castle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Molden-Hauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9618-6940","authenticated-orcid":false,"given":"James","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9718-9596","authenticated-orcid":false,"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9124-354X","authenticated-orcid":false,"given":"Ben","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7350-5622","authenticated-orcid":false,"given":"Arun A.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree","family":"Appu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lih-Ming","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7500-5899","authenticated-orcid":false,"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9261-3618","authenticated-orcid":false,"given":"Katharine","family":"Cuff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pryor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Spain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-6388","authenticated-orcid":false,"given":"Criselle","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2729-5887","authenticated-orcid":false,"given":"Paul J.","family":"Neeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2840-0658","authenticated-orcid":false,"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"74255_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3389\/fonc.2015.00067","volume":"5","author":"A Sankin","year":"2015","unstructured":"Sankin, A., Hakimi, A. A., Hsieh, J. J. & Molina, A. M. Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies. Front. Oncol. 5, 67 (2015).","journal-title":"Front. Oncol."},{"key":"74255_CR2","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1200\/JCO.22.00868","volume":"40","author":"WK Rathmell","year":"2022","unstructured":"Rathmell, W. K. et al. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. J. Clin. Oncol. 40, 2957\u20132995 (2022).","journal-title":"J. Clin. Oncol."},{"key":"74255_CR3","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00345-022-03960-1","volume":"40","author":"V Stuhler","year":"2022","unstructured":"Stuhler, V. et al. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies. World J. Urol. 40, 1175\u20131183 (2022).","journal-title":"World J. Urol."},{"key":"74255_CR4","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.20.02363","volume":"39","author":"DF McDermott","year":"2021","unstructured":"McDermott, D. F. et al. Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma. J. Clin. Oncol. 39, 1020\u20131028 (2021).","journal-title":"J. Clin. Oncol."},{"key":"74255_CR5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s43018-024-00896-w","volume":"6","author":"T Jammihal","year":"2025","unstructured":"Jammihal, T. et al. Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Nat. Cancer 6, 372\u2013384 (2025).","journal-title":"Nat. Cancer"},{"key":"74255_CR6","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ccell.2021.10.001","volume":"39","author":"L Au","year":"2021","unstructured":"Au, L. et al. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell 39, 1497\u20131518 e1411 (2021).","journal-title":"Cancer Cell"},{"key":"74255_CR7","doi-asserted-by":"publisher","first-page":"23721","DOI":"10.1073\/pnas.2001933117","volume":"117","author":"J Chow","year":"2020","unstructured":"Chow, J. et al. Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients. Proc. Natl. Acad. Sci. USA 117, 23721\u201323729 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74255_CR8","doi-asserted-by":"publisher","unstructured":"Chow, J. et al. Tumor and immune remodeling following radiotherapy in human renal cell carcinoma. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2022-006392 (2023).","DOI":"10.1136\/jitc-2022-006392"},{"key":"74255_CR9","doi-asserted-by":"publisher","unstructured":"Lussier, D. M. et al. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proc. Natl. Acad. Sci. USA https:\/\/doi.org\/10.1073\/pnas.2102611118 (2021).","DOI":"10.1073\/pnas.2102611118"},{"key":"74255_CR10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","volume":"81","author":"S Siva","year":"2022","unstructured":"Siva, S. et al. Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma-the RAPPORT trial. Eur. Urol. 81, 364\u2013372 (2022).","journal-title":"Eur. Urol."},{"key":"74255_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","volume":"80","author":"P Cheung","year":"2021","unstructured":"Cheung, P. et al. Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study. Eur. Urol. 80, 693\u2013700 (2021).","journal-title":"Eur. Urol."},{"key":"74255_CR12","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","volume":"22","author":"C Tang","year":"2021","unstructured":"Tang, C. et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 22, 1732\u20131739 (2021).","journal-title":"Lancet Oncol."},{"key":"74255_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.eururo.2022.06.017","volume":"82","author":"M Ali","year":"2022","unstructured":"Ali, M. et al. The role of stereotactic ablative body radiotherapy in renal cell carcinoma. Eur. Urol. 82, 613\u2013622 (2022).","journal-title":"Eur. Urol."},{"key":"74255_CR14","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"74255_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s10238-025-01653-8","volume":"25","author":"Y Pan","year":"2025","unstructured":"Pan, Y. et al. DOCK9 as a predictive biomarker linked to angiogenesis and immune response in esophageal squamous cell carcinoma. Clin. Exp. Med. 25, 126 (2025).","journal-title":"Clin. Exp. Med."},{"key":"74255_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jgg.2015.03.003","volume":"42","author":"H Guo","year":"2015","unstructured":"Guo, H. et al. The PI3K\/AKT pathway and renal cell carcinoma. J. Genet. Genomics 42, 343\u2013353 (2015).","journal-title":"J. Genet. Genomics"},{"key":"74255_CR17","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","volume":"31","author":"BI Rini","year":"2025","unstructured":"Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial. Nat. Med. 31, 3475\u20133484 (2025).","journal-title":"Nat. Med."},{"key":"74255_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","volume":"8","author":"RJ Motzer","year":"2022","unstructured":"Motzer, R. J. et al. Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma. JAMA Oncol. 8, 275\u2013280 (2022).","journal-title":"JAMA Oncol."},{"key":"74255_CR19","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","volume":"26","author":"RJ Motzer","year":"2020","unstructured":"Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN renal 101 trial. Nat. Med. 26, 1733\u20131741 (2020).","journal-title":"Nat. Med."},{"key":"74255_CR20","first-page":"265","volume":"11","author":"A Chao","year":"1984","unstructured":"Chao, A. Nonparametric estimation of the number of classes in a population. Scand. J. Stat. 11, 265\u2013270 (1984).","journal-title":"Scand. J. Stat."},{"key":"74255_CR21","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.it.2025.06.003","volume":"46","author":"CL Guo","year":"2025","unstructured":"Guo, C. L., Wang, C. S., Wang, X. H., Yu, D. & Liu, Z. GZMK(+)CD8(+) T cells: multifaceted roles beyond cytotoxicity. Trends Immunol. 46, 562\u2013572 (2025).","journal-title":"Trends Immunol."},{"key":"74255_CR22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.4049\/jimmunol.2300083","volume":"211","author":"D Duquette","year":"2023","unstructured":"Duquette, D. et al. Human granzyme K is a feature of innate T cells in blood, tissues, and tumors, responding to cytokines rather than TCR stimulation. J. Immunol. 211, 633\u2013647 (2023).","journal-title":"J. Immunol."},{"key":"74255_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373\u2013377 (2015).","journal-title":"Nature"},{"key":"74255_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60\u201365 (2017).","journal-title":"Nature"},{"key":"74255_CR25","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1073\/pnas.1705327114","volume":"114","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst, A. O. et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl. Acad. Sci. USA 114, 4993\u20134998 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74255_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18570-x","volume":"11","author":"Q Peng","year":"2020","unstructured":"Peng, Q. et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat. Commun. 11, 4835 (2020).","journal-title":"Nat. Commun."},{"key":"74255_CR27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst, J., Ahrends, T., B\u0105ba\u0142a, N., Melief, C. J. M. & Kastenm\u00fcller, W. CD4+ T cell help in cancer immunology and immunotherapy. Nat. Rev. Immunol. 18, 635\u2013647 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"74255_CR28","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251\u20131259 (2019).","journal-title":"Nat. Med."},{"key":"74255_CR29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","volume":"579","author":"TD Wu","year":"2020","unstructured":"Wu, T. D. et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274\u2013278 (2020).","journal-title":"Nature"},{"key":"74255_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41392-019-0077-2","volume":"4","author":"X Li","year":"2019","unstructured":"Li, X., Wang, M. & Xiang, R. Clonal replacement of novel T cells: a new phenomenon in the tumor microenvironment following PD-1 blockade. Signal Transduct. Target. Ther. 4, 43 (2019).","journal-title":"Signal Transduct. Target. Ther."},{"key":"74255_CR31","doi-asserted-by":"publisher","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2017","unstructured":"Simon, S. & Labarriere, N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology 7, e1364828 (2017).","journal-title":"Oncoimmunology"},{"key":"74255_CR32","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/s41590-024-01843-8","volume":"25","author":"X Lan","year":"2024","unstructured":"Lan, X. et al. Antitumor progenitor exhausted CD8+ T cells are sustained by TCR engagement. Nat. Immunol. 25, 1046\u20131058 (2024).","journal-title":"Nat. Immunol."},{"key":"74255_CR33","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow, A., Perica, K., Klebanoff, C. A. & Wolchok, J. D. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19, 775\u2013790 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"74255_CR34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41586-024-08076-7","volume":"636","author":"MA Cardenas","year":"2024","unstructured":"Cardenas, M. A. et al. Differentiation fate of a stem-like CD4 T cell controls immunity to cancer. Nature 636, 224\u2013232 (2024).","journal-title":"Nature"},{"key":"74255_CR35","doi-asserted-by":"publisher","unstructured":"Carlisle, J. W. et al. Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2022-004803 (2022).","DOI":"10.1136\/jitc-2022-004803"},{"key":"74255_CR36","doi-asserted-by":"publisher","first-page":"e000328","DOI":"10.1136\/bmjonc-2024-000328","volume":"3","author":"CO Rebecca","year":"2024","unstructured":"Rebecca, C. O. et al. Characterisation of clinical response and transcriptional profiling of proliferating CD8 T cells in the blood of cancer patients after PD-1 monotherapy or combination therapy. BMJ Oncol. 3, e000328 (2024).","journal-title":"BMJ Oncol."},{"key":"74255_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijrobp.2020.06.007","volume":"108","author":"KLM Chua","year":"2020","unstructured":"Chua, K. L. M. et al. High-dimensional characterization of the systemic immune landscape informs on synergism between radiation therapy and immune checkpoint blockade. Int. J. Radiat. Oncol. Biol. Phys. 108, 70\u201380 (2020).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"74255_CR38","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41581-023-00700-5","volume":"19","author":"MM Wolf","year":"2023","unstructured":"Wolf, M. M., Rathmell, W. K. & de Cubas, A. A. Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens. Nat. Rev. Nephrol. 19, 440\u2013450 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"74255_CR39","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","volume":"38","author":"RJ Motzer","year":"2020","unstructured":"Motzer, R. J. et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell 38, 803\u2013817 e804 (2020).","journal-title":"Cancer Cell"},{"key":"74255_CR40","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.2147\/JIR.S457570","volume":"17","author":"X Yang","year":"2024","unstructured":"Yang, X. et al. Single-cell analysis identifies distinct populations of cytotoxic CD4(+) T cells linked to the therapeutic efficacy of immune checkpoint inhibitors in metastatic renal cell carcinoma. J. Inflamm. Res. 17, 4505\u20134523 (2024).","journal-title":"J. Inflamm. Res."},{"key":"74255_CR41","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen, C. S. et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576, 465\u2013470 (2019).","journal-title":"Nature"},{"key":"74255_CR42","doi-asserted-by":"publisher","unstructured":"Jansen, C. S. et al. Immune niches in brain metastases contain TCF1+ stem-like T cells, are associated with disease control and are modulated by preoperative SRS. Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-2722744\/v1 (2023).","DOI":"10.21203\/rs.3.rs-2722744\/v1"},{"key":"74255_CR43","doi-asserted-by":"publisher","unstructured":"Shen, Y. et al. Radiation and anti-PD-L1 synergize by stimulating a stem-like T cell population in the tumor-draining lymph node. Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-3921977\/v1 (2024).","DOI":"10.21203\/rs.3.rs-3921977\/v1"},{"key":"74255_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58510-1","volume":"16","author":"Y Shen","year":"2025","unstructured":"Shen, Y. et al. Combination radiation and alphaPD-L1 enhance tumor control by stimulating CD8+ PD-1+ TCF-1+ T cells in the tumor-draining lymph node. Nat. Commun. 16, 3522 (2025).","journal-title":"Nat. Commun."},{"key":"74255_CR45","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1084\/jem.20092140","volume":"207","author":"SL Jongbloed","year":"2010","unstructured":"Jongbloed, S. L. et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 207, 1247\u20131260 (2010).","journal-title":"J. Exp. Med."},{"key":"74255_CR46","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1084\/jem.20100348","volume":"207","author":"A Bachem","year":"2010","unstructured":"Bachem, A. et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J. Exp. Med. 207, 1273\u20131281 (2010).","journal-title":"J. Exp. Med."},{"key":"74255_CR47","doi-asserted-by":"publisher","unstructured":"Patin, E. C. et al. Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-004306 (2022).","DOI":"10.1136\/jitc-2021-004306"},{"key":"74255_CR48","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1182\/blood-2007-09-114389","volume":"112","author":"J Helft","year":"2008","unstructured":"Helft, J. et al. Antigen-specific T-T interactions regulate CD4 T-cell expansion. Blood 112, 1249\u20131258 (2008).","journal-title":"Blood"},{"key":"74255_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1146791","volume":"14","author":"A Ghosh","year":"2023","unstructured":"Ghosh, A. et al. CD38: an ecto-enzyme with functional diversity in T cells. Front. Immunol. 14, 1146791 (2023).","journal-title":"Front. Immunol."},{"key":"74255_CR50","doi-asserted-by":"crossref","unstructured":"Salvador, R. et al. HLA-DR expression in cytotoxic T lymphocytes: a key to boost the therapeutic potential of T cell-based strategies for breast cancer. Front. Immunol. 16, 1653970 (2025).","DOI":"10.3389\/fimmu.2025.1653970"},{"key":"74255_CR51","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","volume":"185","author":"AM Luoma","year":"2022","unstructured":"Luoma, A. M. et al. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell 185, 2918\u20132935 e2929 (2022).","journal-title":"Cell"},{"key":"74255_CR52","doi-asserted-by":"publisher","unstructured":"Lhuillier, C. et al. Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI138740 (2021).","DOI":"10.1172\/JCI138740"},{"key":"74255_CR53","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","volume":"181","author":"DY Oh","year":"2020","unstructured":"Oh, D. Y. et al. Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 181, 1612\u20131625 e1613 (2020).","journal-title":"Cell"},{"key":"74255_CR54","doi-asserted-by":"publisher","unstructured":"Cachot, A. et al. Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.abe3348 (2021).","DOI":"10.1126\/sciadv.abe3348"},{"key":"74255_CR55","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0002-9440(10)63844-8","volume":"162","author":"EC Ibrahim","year":"2003","unstructured":"Ibrahim, E. C. et al. Altered pattern of major histocompatibility complex expression in renal carcinoma: tumor-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma. Am. J. Pathol. 162, 501\u2013508 (2003).","journal-title":"Am. J. Pathol."},{"key":"74255_CR56","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0304-3835(97)04754-X","volume":"115","author":"T Saito","year":"1997","unstructured":"Saito, T., Kimura, M., Kawasaki, T., Sato, S. & Tomita, Y. MHC class II antigen-associated invariant chain on renal cell cancer may contribute to the anti-tumor immune response of the host. Cancer Lett. 115, 121\u2013127 (1997).","journal-title":"Cancer Lett."},{"key":"74255_CR57","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0022-5347(01)66661-8","volume":"155","author":"G Gastl","year":"1996","unstructured":"Gastl, G. et al. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma. J. Urol. 155, 361\u2013367 (1996).","journal-title":"J. Urol."},{"key":"74255_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15959-6","volume":"11","author":"XD Liu","year":"2020","unstructured":"Liu, X. D. et al. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat. Commun. 11, 2135 (2020).","journal-title":"Nat. Commun."},{"key":"74255_CR59","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","volume":"77","author":"R Lugano","year":"2020","unstructured":"Lugano, R., Ramachandran, M. & Dimberg, A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol. Life Sci. 77, 1745\u20131770 (2020).","journal-title":"Cell Mol. Life Sci."},{"key":"74255_CR60","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/jcp.21706","volume":"219","author":"G Ferrari","year":"2009","unstructured":"Ferrari, G., Cook, B. D., Terushkin, V., Pintucci, G. & Mignatti, P. Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J. Cell Physiol. 219, 449\u2013458 (2009).","journal-title":"J. Cell Physiol."},{"key":"74255_CR61","doi-asserted-by":"publisher","first-page":"16297","DOI":"10.18632\/oncotarget.24631","volume":"9","author":"P Mallikarjuna","year":"2018","unstructured":"Mallikarjuna, P., Sitaram, R. T., Landstrom, M. & Ljungberg, B. VHL status regulates transforming growth factor-beta signaling pathways in renal cell carcinoma. Oncotarget 9, 16297\u201316310 (2018).","journal-title":"Oncotarget"},{"key":"74255_CR62","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s00240-002-0245-6","volume":"30","author":"A Hegele","year":"2002","unstructured":"Hegele, A. et al. TGF-beta1 in patients with renal cell carcinoma. Urol. Res. 30, 126\u2013129 (2002).","journal-title":"Urol. Res."},{"key":"74255_CR63","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1038\/sj.bjc.6605298","volume":"101","author":"JJ Patard","year":"2009","unstructured":"Patard, J. J. et al. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br. J. Cancer 101, 1417\u20131424 (2009).","journal-title":"Br. J. Cancer"},{"key":"74255_CR64","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","volume":"84","author":"ER Plimack","year":"2023","unstructured":"Plimack, E. R. et al. Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study. Eur. Urol. 84, 449\u2013454 (2023).","journal-title":"Eur. Urol."},{"key":"74255_CR65","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277\u20131290 (2018).","journal-title":"N. Engl. J. Med."},{"key":"74255_CR66","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1860482","volume":"10","author":"SD van Asten","year":"2021","unstructured":"van Asten, S. D. et al. T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-gamma, TNF-alpha or IL-2 production. Oncoimmunology 10, 1860482 (2021).","journal-title":"Oncoimmunology"},{"key":"74255_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.952252","volume":"12","author":"Y Xu","year":"2022","unstructured":"Xu, Y. et al. Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded clones with unique phenotypes. Front. Oncol. 12, 952252 (2022).","journal-title":"Front. Oncol."},{"key":"74255_CR68","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1038\/bjc.2015.96","volume":"112","author":"V Baldan","year":"2015","unstructured":"Baldan, V., Griffiths, R., Hawkins, R. E. & Gilham, D. E. Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma. Br. J. Cancer 112, 1510\u20131518 (2015).","journal-title":"Br. J. Cancer"},{"key":"74255_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 14, 7 (2013).","journal-title":"BMC Bioinforma."},{"key":"74255_CR70","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"74255_CR71","doi-asserted-by":"publisher","unstructured":"Sergushichev, A. A. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/060012 (2016).","DOI":"10.1101\/060012"},{"key":"74255_CR72","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"74255_CR73","doi-asserted-by":"crossref","unstructured":"McInnes, et al. UMAP: Uniform Manifold Approximation and Projection. J. Open Source Softw. 3, 861 (2018).","DOI":"10.21105\/joss.00861"},{"key":"74255_CR74","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nmeth.3364","volume":"12","author":"DA Bolotin","year":"2015","unstructured":"Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380\u2013381 (2015).","journal-title":"Nat. Methods"},{"key":"74255_CR75","unstructured":"Popov, A. et al. immunomind\/immunarch: 0.10.3.9002. Zenodo https:\/\/zenodo.org\/records\/17640286 (2025)."},{"key":"74255_CR76","doi-asserted-by":"crossref","unstructured":"Wickham, H. Elegant Graphics for Data Analysis - ggplot2 (Springer, 2016).","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"74255_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37822-0","volume":"14","author":"Y Feng","year":"2023","unstructured":"Feng, Y. et al. Spatial analysis with SPIAT and spaSim to characterize and simulate tissue microenvironments. Nat. Commun. 14, 2697 (2023).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74255-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74255-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74255-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:01:51Z","timestamp":1786924911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74255-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74255"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74255-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.J.N. had research funding from Roche Genentech, B.M.S., M.S.D., CRISPR Therapeutics and Beigene. S.S. had research funding from M.S.D., Varian, Bayer Pharmaceuticals and speaker honoraria from Accuray.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8453"}}